Category Archives: Hypogonadism

This thorough and in-depth presentation on the global Testosterone Cypionate market is a ready-to-refer market research presentation that offers high end cues and actionable insights to various market participants and players operating across regional and global areas to secure growth, sustenance and uncompromised revenue pools. Continue reading →

During a virtual Case Based Peer Perspectives event, Nicholas J. Continue reading →

Global Hormone Replacement Therapy Market: Overview Hormone replacement therapy refers to the treatment of the patients with growth hormone deficiency due to conditions such as dwarfism or women nearing menopause, which requires replacement of hormones in the body whose levels have become low. Currently, a combination of drugs are used to treat hormone deficiencies, which are known to have better safety and efficacy parameter. Globally, the cases of hormone deficiency is escalating and a vast patient base are deprived of the proper treatment. Continue reading →

A scientist from the University of Sheffield who pioneered the first licenced therapy for children with a chronic hormone deficiency has been honoured with a prestigious international award. Richard Ross, Professor of Endocrinology at the University of Sheffield, has been recognised with the 2021 Outstanding Innovation Laureate Award from the Endocrine Society one of the top honours in the field. Continue reading →

By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Up and Coming Milestones Tlando PDUFA date August 28, 2020 Primary endpoint results for LiFT (LPCN 1144) 4Q:20 Patent Infringement trial February 2021 Complete Phase II LiFT (LPCN 1144) 2Q:21 Second Quarter 2020 Operational and Financial Results On August 6, 2020 Lipocine (NASDAQ:LPCN) filed its second quarter 2020 10-Q and posted its earnings release for the three month period ending June 30, 2020. The company reported zero revenues and a net loss per share of ($0.13) compared to prior year revenues of zero and loss of ($0.14) per share. Continue reading →

BUFFALO, N.Y. Continue reading →

Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ZolpiMist sublicensee SUDA Pharmaceuticals Ltd ("SUDA"), enables near-term commercialization of ZolpiMist in Australia. Continue reading →

Andropause or male menopause has to do with the declining hormonal levels in older men. Read on to know the symptoms, causes and treatment of this condition. We often talk about how women suffer from menopause and how it affects their health. Continue reading →

Male Hypogonadism Market Industry Forecast To 2026 Garner Insights has titled a new research report named as Male Hypogonadism Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate Continue reading →

The global Male Hypogonadism market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism market player in a comprehensive way. Continue reading →